Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 10,235 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neoplasms, Connective Tissue Clear all
Terminated Phase 3 Interventional

Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

NCT00009906
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
Imatinib Mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
132
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 99 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Sep 12, 2026, 8:23 AM EDT
Recruiting Not applicable Interventional

Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)

NCT07629206
View directory record Official record
Conditions
Low-Risk, Early Stage Breast Cancer
Interventions
Cryoablation
Device
Lead sponsor
IceCure Medical Ltd.
Industry
Eligibility
70 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
2
States / cities
Glendale, California • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 12, 2026, 8:23 AM EDT
Recruiting Phase 2 Interventional

Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts

NCT07806617
View directory record Official record
Conditions
Warts, Verruca (Warts), Verruca Vulgaris
Interventions
9-valent human papillomavirus vaccine, Sterile Saline
Biological · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

NCT01997190
View directory record Official record
Conditions
Malignant Pleural Effusion, Lung Cancer, Mesothelioma, Breast Cancer, Ovarian Cancer
Interventions
AdV-tk + valacyclovir
Biological
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

A Study of ASN007 in Patients With Advanced Solid Tumors

NCT03415126
View directory record Official record
Conditions
Cancer, Malignancy, Neoplasia, Neoplasm, Neoplasm Metastasis, Colon Cancer, Colonic Neoplasms, Colon Cancer Liver Metastasis, Metastatic Cancer, Metastatic Melanoma, Metastatic Colon Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer Metastatic, Pancreatic Cancer, Pancreas Cancer, Pancreas Adenocarcinoma, Pancreas Neoplasm, Metastatic Nonsmall Cell Lung Cancer, Metastatic Pancreatic Cancer
Interventions
ASN007: ascending doses, ASN007 RD
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Tampa, Florida • Boston, Massachusetts • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 12, 2026, 8:23 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sun Safe Workplaces: A Campaign on Sun Protection Policies for Outdoor Workers Phase I

NCT02824289
View directory record Official record
Conditions
Skin Cancer
Interventions
Sun Safe Workplaces Program, Attention Control
Behavioral
Lead sponsor
Klein Buendel, Inc.
Industry
Eligibility
18 Years and older
Enrollment
825 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
3
States / cities
Oakland, California • Aurora, Colorado • Golden, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer

NCT00828074
View directory record Official record
Conditions
Breast Cancer
Interventions
sorafenib tosylate, vinorelbine ditartrate
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccination With Flt3L, Radiation, and Poly-ICLC

NCT03789097
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
Pembrolizumab, Flt3L, Radiation, Poly ICLC
Drug · Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 12, 2026, 8:23 AM EDT
Recruiting Phase 2 Interventional

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

NCT06961006
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Intismeran autogene, Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Springdale, Arkansas • San Francisco, California • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma

NCT03068455
View directory record Official record
Conditions
Melanoma
Interventions
nivolumab, ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
1,844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
33
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Sep 12, 2026, 8:23 AM EDT
Terminated Phase 2 Interventional

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

NCT03979508
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Breast Fibrocystic Change, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Abemaciclib, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 12, 2026, 8:23 AM EDT
Not listed Not applicable Interventional

Iyengar Yoga Therapy for Dysmenorrhea and Endometriosis

NCT03784976
View directory record Official record
Conditions
Secondary Dysmenorrhea, Dysmenorrhea, Dysmenorrhea Secondary, Polycystic Ovary Syndrome, Endometriosis, Fibroid, Menstrual Pain, Menstrual Disorder, Menstrual Discomfort
Interventions
Iyengar Yoga Therapy
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
12 Years to 65 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 23, 2018 · Synced Sep 12, 2026, 8:23 AM EDT
Terminated Phase 2 Interventional

Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients

NCT03342417
View directory record Official record
Conditions
Breast Cancer Female, Ovarian Cancer, Gastric Cancer
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
ExcellaBio LLC
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 12, 2026, 8:23 AM EDT
Terminated Not applicable Interventional Results available

Study of Preoperative Boost Radiotherapy

NCT02482389
View directory record Official record
Conditions
Breast Cancer
Interventions
Single fraction of 7 Gy
Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 12, 2026, 8:23 AM EDT
Recruiting Phase 1 Interventional

HER2 Vaccine for Locally Advanced Breast Cancer

NCT06949410
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer
Interventions
HER2 Vaccine
Drug
Lead sponsor
Pravin T.P Kaumaya
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03812510
View directory record Official record
Conditions
Common Wart
Interventions
A-101
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
1 Year and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
46
States / cities
Mobile, Alabama • Glendale, Arizona • Fort Smith, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers

NCT02550210
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast Cancer Locator (BCL)
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 12, 2026, 8:23 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

NCT00999557
View directory record Official record
Conditions
Alopecia, Breast Cancer
Interventions
bimatoprost ophthalmic solution, placebo
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 12, 2026, 8:23 AM EDT
Not listed Phase 1Phase 2 Interventional

Circadian Thermal Sensing to Detect Breast Disease

NCT02511301
View directory record Official record
Conditions
Early-Stage Breast Carcinoma
Interventions
Cyrcadia CBR™ device placement for abnormality screening
Device
Lead sponsor
Cyrcadia Health
Industry
Eligibility
21 Years and older · Female only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Mountain View, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Sep 12, 2026, 8:23 AM EDT
Terminated No phase listed Observational

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

NCT01096381
View directory record Official record
Conditions
Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer

NCT00296036
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pyridoxine hydrochloride, urea/lactic acid-based topical cream, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
231
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 148 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 12, 2026, 8:23 AM EDT
Suspended Phase 1 Interventional

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

NCT05378464
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Dendritic Cell (DC1) Vaccine, Trastuzumab, Pepinemab, T-Cell therapy
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 4 Interventional

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

NCT01742299
View directory record Official record
Conditions
GIST and CML
Interventions
imatinib mesylate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 100 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 12, 2026, 8:23 AM EDT